eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma
International Journal of Molecular Sciences · 20.01.2023 · 24 (3) · 2055
DOI: 10.3390/ijms24032055 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.01.2023. Verfasst von Sara M Steinmann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Tumor Pathology, Institute of Pathology, University Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, University of Sassari, Italian Association Against Cancer (AIRC).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a primary liver tumor with high lethality and increasing incidence worldwide. While tumor resection or liver transplantation is effective in the early stages of the disease, the therapeutic options for advanced HCC remain limited and the benefits are temporary. Thus, novel therapeutic targets and more efficacious treatments against this deadly cancer are urgently needed. Here, we investigated the pathogenetic and therapeutic role of eukaryotic initiation factor 4A1 (eIF4A1) in this tumor type. We observed consistent eIF4A1 upregulation in HCC lesions compared with non-tumorous surrounding liver tissues. In addition, eIF4A1 levels were negatively correlated with the prognosis of HCC patients. In HCC lines, the exposure to various eIF4A inhibitors triggered a remarkable decline in proliferation and augmented apoptosis, paralleled by the inhibition of several oncogenic pathways. Significantly, anti-growth effects were achieved at nanomolar concentrations of the eIF4A1 inhibitors and were further increased by the simultaneous administration of the pan mTOR inhibitor, Rapalink-1. In conclusion, our results highlight the pathogenetic relevance of eIF4A1 in HCC and recommend further evaluation of the potential usefulness of pharmacological combinations based on eIF4A and mTOR inhibitors in treating this aggressive tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Tumor Pathology, Institute of Pathology, University Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
- Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, Spain.
- Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy.
- Therapeutic Innovation Laboratory, UMR7200, CNRS/University of Strasbourg, CEDEX, 67401 Illkirch, France.
ORCID-Profile: Sara M Steinmann, Antonio Cigliano, Giovanni M Pes, Laurent Desaubry, Jose J G Marin
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- University of Sassari
- Italian Association Against Cancer (AIRC)
- Fondo di Ateneo per la Ricerca 2019 from the University of Sassari (Sassari, Italy)
Zitieren
APA
Steinmann, S. M., Sánchez-Martín, A., Tanzer, E., Cigliano, A., Pes, G. M., Simile, M. M., Desaubry, L., Marin, J. J. G., Evert, M., & Calvisi, D. F. (2023). eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma. International Journal of Molecular Sciences, 24(3), 2055. https://doi.org/10.3390/ijms24032055
Vancouver
Steinmann SM, Sánchez-Martín A, Tanzer E, Cigliano A, Pes GM, Simile MM, et al. eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023;24(3):2055. doi:10.3390/ijms24032055
BibTeX
@article{Steinmann2023,
author = {Steinmann, Sara M and Sánchez-Martín, Anabel and Tanzer, Elisabeth and Cigliano, Antonio and Pes, Giovanni M and Simile, Maria M and Desaubry, Laurent and Marin, Jose J G and Evert, Matthias and Calvisi, Diego F},
title = {eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {3},
pages = {2055},
doi = {10.3390/ijms24032055}
}
EUVIMED